These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3922441)

  • 21. Tranylcypromine isomers in the treatment of Parkinson's disease. Biochemical effects.
    Reynolds GP; Riederer P
    Int Pharmacopsychiatry; 1981; 16(1):30-3. PubMed ID: 7298269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tranylcypromine lowers human platelet MAO B activity but not concentration.
    Fritz RR; Malek-Ahmadi P; Rose RM; Denney RM; Abell CW
    Biol Psychiatry; 1983 Jun; 18(6):685-94. PubMed ID: 6871302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MAO inhibition as antidepressive mechanism reevaluated. A controlled study with tranylcypromine isomers.
    Beckmann H; Moises HW
    Mod Probl Pharmacopsychiatry; 1983; 19():211-4. PubMed ID: 6865965
    [No Abstract]   [Full Text] [Related]  

  • 24. An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced parkinsonism.
    Perényi A; Bagdy G; Arató M
    Pharmacopsychiatria; 1983 Sep; 16(5):143-6. PubMed ID: 6140692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyramine pressor sensitivity changes during deprenyl treatment.
    Sunderland T; Mueller EA; Cohen RM; Jimerson DC; Pickar D; Murphy DL
    Psychopharmacology (Berl); 1985; 86(4):432-7. PubMed ID: 3929314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma.
    Youdim MB; Aronson JK; Blau K; Green AR; Grahame-Smith DG
    Psychol Med; 1979 May; 9(2):377-82. PubMed ID: 472083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor, in endogenous and nonendogenous depression.
    Mann JJ; Frances A; Peselow ED; Gershon S
    Psychopharmacol Bull; 1982 Oct; 18(4):182-4. PubMed ID: 6818606
    [No Abstract]   [Full Text] [Related]  

  • 28. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet monoamine oxidase in unipolar and bipolar depression.
    Trivedi JK; Lal N; Singh RP; Viswanathan PN
    Indian J Med Res; 1988 Aug; 88():165-8. PubMed ID: 3198176
    [No Abstract]   [Full Text] [Related]  

  • 30. A placebo-controlled trial of L-deprenyl in atypical depression.
    McGrath PJ; Stewart JW; Harrison W; Wager S; Nunes EN; Quitkin FM
    Psychopharmacol Bull; 1989; 25(1):63-7. PubMed ID: 2505303
    [No Abstract]   [Full Text] [Related]  

  • 31. Elevated platelet monoamine oxidase activity in patients wth nonendogenous depression.
    White K; Shih J; Fong T; Young H; Gelfand R; Boyd J; Simpson G; Sloane RB
    Am J Psychiatry; 1980 Oct; 137(10):1258-9. PubMed ID: 7416279
    [No Abstract]   [Full Text] [Related]  

  • 32. Monoamine oxidase inhibitors revisited: what you should know.
    Goldberg JF; Thase ME
    J Clin Psychiatry; 2013 Feb; 74(2):189-91. PubMed ID: 23473352
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical efficacy of deprenyl, a specific inhibitor of MAOB.
    Psychopharmacol Bull; 1983; 19(3):328-42. PubMed ID: 6314420
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
    Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
    J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
    Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the clinical significance of an elevated platelet MAO level?
    Pies RW
    J Clin Psychopharmacol; 1996 Dec; 16(6):472-3. PubMed ID: 8959484
    [No Abstract]   [Full Text] [Related]  

  • 37. [Blood platelet MAO activity in endogenous depressive syndrome].
    Puzyński S; Hauptmann M; Załuska M
    Psychiatr Pol; 1980; 14(6):575-80. PubMed ID: 7232599
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of single doses of tranylcypromine on platelet MAO and amine uptake in normal subjects.
    Gentil V; Alevizos B; Lader M
    Biochem Pharmacol; 1978; 27(8):1197-201. PubMed ID: 697920
    [No Abstract]   [Full Text] [Related]  

  • 39. L-deprenyl plus L-phenylalanine in the treatment of depression.
    Birkmayer W; Riederer P; Linauer W; Knoll J
    J Neural Transm; 1984; 59(1):81-7. PubMed ID: 6425455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tranylcypromine and inhibition of MAO activity.
    Bowden CL
    J Clin Psychopharmacol; 1984 Jun; 4(3):172-3. PubMed ID: 6736280
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.